Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
shorts were just waiting to pounce and here we go
Guessing the low float makes it harder to short and manipulate like crazy.
Well, that's a good start anyway, and the market
sure is positively noticing the company as the
rising sp indicates.
Time will tell if RDHL sp momentum continues!
I for one am cautiously optimistic!
$RDHL RedHill Biopharma
https://finance.yahoo.com/news/three-undiscovered-gems-united-states-150814759.html
Overview: RedHill Biopharma Ltd. is a specialty biopharmaceutical company that primarily focuses on gastrointestinal and infectious diseases, with a market cap of $256.99 million.
Operations: RedHill Biopharma Ltd. derives its revenue from the sale of specialty biopharmaceutical products targeting gastrointestinal and infectious diseases. The company has a market cap of $256.99 million.
RedHill Biopharma, a small cap stock, recently reported a significant one-off gain of US$54.6M for the year ending December 31, 2023. The company is debt-free and has maintained this status for over five years. Despite becoming profitable last year, its share price has been highly volatile over the past three months. Recent developments include the launch of Talicia in the UAE and positive results from studies on opaganib for Type 2 diabetes treatment.
They have some revenue but its nothing that will make wall street excited. They need something game changing at this point to get the attention of investors
9.26 +0.73 (+8.66%)
As of 10:13 AM EDT. Market Open
Cool.
Talicia® Launched in the United Arab Emirates
https://finance.yahoo.com/news/talicia-launched-united-arab-emirates-110000964.html
In this article:
RedHill's Talicia, the first approved low-dose rifabutin-containing all-in-one combination treatment for H. pylori, is now available on prescription to treat adults with H. pylori infection in the United Arab Emirates (UAE)
The commercial launch of Talicia triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales
Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists[1] for the treatment of H. pylori, a bacterial infection that affects 41% of the UAE population[2] and over 50% of the world's adult population[3]
RALEIGH, N.C., Aug. 21, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the launch of Talicia (omeprazole magnesium, amoxicillin and rifabutin)[4] in the United Arab Emirates (UAE) – making it available by prescription to treat adults with Helicobacter pylori (H. pylori) infection. The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales. Talicia is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori.
"We are delighted with the commercial launch of Talicia in the UAE, bringing this important medicine to patients in the region," said Rick Scruggs, President, RedHill Biopharma Inc. & Chief Commercial Officer. "As one of the strongest risk factors for gastric cancer, H. pylori is a major public health concern. With 41% of the UAE population infected by H. pylori and the alarming failure rates of clarithromycin-based therapies[5],[6], there is a significant medical need for a highly effective first-line H. pylori therapy. Our efforts to make Talicia available to patients in more countries continue as we work to explore additional opportunities with existing and potential partners."
Clarithromycin-based triple therapy continues to wane in effectiveness. A 2021 study demonstrated only 68.5% eradication with traditional clarithromycin-based triple therapy, which declined further to 32% in patients harboring resistant H. pylori organisms[7]. Clarithromycin-based treatment efficacy can also be negatively impacted by patient obesity or diabetic status, neither of which impact Talicia's safety or efficacy, according to data from post-approval post-hoc analysis[8],[9].
About H. pylori
H. pylori is a bacterial infection that affects approximately 35%[10] of the U.S. population, with an estimated two million patients treated annually[11]. Worldwide, more than 50% of the population has H. pylori infection, which is classified by the WHO as a Group 1 carcinogen. It remains the strongest known risk factor for gastric cancer[12] and a major risk factor for peptic ulcer disease[13] and gastric mucosa-associated lymphoid tissue (MALT) lymphoma[14]. More than 27,000 Americans are diagnosed with gastric cancer annually[15]. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H. pylori-positive due to high resistance of H. pylori to antibiotics – especially clarithromycin – which is still commonly used in standard combination therapies[16].
About Talicia
Talicia is the only low-dose rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria seen with other antibiotics. The high rates of H. pylori resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based therapies and are a strong public health concern, as highlighted by the ACG, FDA and the World Health Organization (WHO) in recent years.
Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole). In November 2019, Talicia was approved by the U.S. FDA for the treatment of H. pylori infection in adults. In the pivotal Phase 3 study, Talicia demonstrated 84% eradication of H. pylori infection in the intent-to-treat (ITT) group vs. 58% in the active comparator arm (p<0.0001). Minimal to zero resistance to rifabutin, a key component of Talicia, was detected in RedHill's pivotal Phase 3 study. Further, in an analysis of data from this study, it was observed that subjects who were confirmed adherent[17] to their therapy had response rates of 90.3% in the Talicia® arm vs. 64.7% in the active comparator arm[18].
Talicia is eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents which extend patent protection until 2034 with additional patents and applications pending and granted in various territories worldwide.
TALICIA: INDICATION AND IMPORTANT SAFETY INFORMATION
Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial, indicated for the treatment of Helicobacter pylori infection in adults.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
IMPORTANT SAFETY INFORMATION
Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycin.
Talicia is contraindicated in patients receiving rilpivirine-containing products.
Talicia is contraindicated in patients receiving delavirdine or voriconazole.
Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin.
Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Talicia.
Severe cutaneous adverse reactions (SCAR) (e.g., Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)) have been reported with rifabutin, amoxicillin, and omeprazole. Additionally, drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rifabutin.
Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis.
Talicia may cause fetal harm. Talicia is not recommended for use in pregnancy. Talicia may reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.
Talicia should not be used in patients with hepatic impairment or severe renal impairment.
Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease.
The most common adverse reactions (=1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.
To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Full prescribing information for Talicia is available at www.Talicia.com
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults[19], and Aemcolo®, for the treatment of travelers' diarrhea in adults[20]. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease.
More information about the Company is available at www.redhillbio.com / twitter.com/RedHillBio.
Not saying it wont happen but more likely why has it not happened. I mean especially when they are desperate for money you would think somebody could cut a deal with them for a steal.
8.21 +0.18 (+2.22%)
As of 1:46 PM EDT. Market Open.
This i did not expect!!!
But again if all these studies were so great why is nobody partnering with them or giving them any money? Talicia sales are not very good so really they got no revenue to speak of. I fear now with the price higher they are ready for a big fat offering.
7.98 -0.05 (-0.59%)
As of 11:36 AM EDT. Market Open.
Now, that is a very pleasant surprise.
If there was any good news it would have been released to avoid the split. They got nothing.
What good news all we get is fulff on studies followed by dilution. If the results of any of these studies were so great somebody would parnter with them or give them money. Yet nobody does which tells me its just pr bs to drive up the stock price before the offering, etc. I am pretty much done at this point. I dont have any faith in them anymore. Kicking myself for not selling it all before today as I knew I should have. This stock will be 4 bucks within a month.
Unless some good news, RDHL
is doomed!
as expected stock gettting crushed after the split.I dont short but if i did would have been a very easy short.
That is what they always do after a reverse split. Reverse splits almost never ever work out all they do is crush shareholders. Look at the last reverse split was done at 5 bucks and we went down to .30 cents. Shorts have a total field day with a reverse split and a company should never ever do one unless they they have zero other options.
Why are people / sellers are selling shares so cheap! Sellers are creating drop of the price / chaos. Weak sellers we have!
Just a t typical rdhl pump before tomorrow. Once the split happens the shorts will tank this thing very fast. If they had any real good news they would have already released it to avoid the reverse split. Simply rinse and repeat
$RDHL https://t.co/i37zgm7Iq7https://t.co/HzBpDr4C4H
— Viewmont (@viewmont12) August 19, 2024
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
https://finance.yahoo.com/news/redhill-announces-positive-obesity-diabetes-110000454.html
The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034[1] – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's Ozempic® and Wegovy® and Eli Lilly's Trulicity® and Mounjaro® and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim's Jardiance®
Positive results from multiple in vivo studies show the impact of sphingosine kinase-2 (SPHK2) inhibition in various models of metabolic disease, supporting the potential of opaganib therapy for diabetes and obesity-related disorders
With multiple U.S. government collaborations ongoing, opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule drug with demonstrated safety & efficacy profiles. It is in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications, including COVID-19, Ebola, acute respiratory distress syndrome (ARDS) and radio/chemical protection
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 19, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive results from multiple in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation, showing the impact of opaganib[2] on weight gain and glucose tolerance in a high fat diet (HFD) model, supporting the potential clinical use of opaganib for the prevention and therapy of Type 2 diabetes and other obesity-related disorders.
"Sphingolipid metabolism is implicated in insulin resistance, ß-cell disruption, adipocyte function, inflammation and immune regulation, vascular complications and energy metabolism – all significant components of obesity, diabetes and their associated complications," said Charles D. Smith, Ph.D. Founder and CEO of Apogee Biotechnology Corporation. "Opaganib's ability to modulate multiple signaling pathways through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells provides a strong rationale for evaluation of opaganib in obesity-related disorders."
The studies were designed to examine some of the most fundamental aspects of diabetes and obesity-related disease. The encouraging outcomes showed the benefit of opaganib therapy in suppression of HFD-induced body weight gain, loss of glucose tolerance and fat deposition. Additionally, opaganib treatment reduced weight gain and restored glucose tolerance in an already obese HFD model, suggesting its potential for treating, not just preventing, obesity-related disorders.
"Sphingolipid metabolism is a key pathway in many diseases, including obesity, but has not been adequately examined as a therapeutic target for human therapy," said Dr. Mark Levitt, Chief Scientific Officer at RedHill. "Opaganib, which acts as a sphingosine competitor, is the first clinical drug to target three key enzymes in this pathway."
The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034 – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's Ozempic and Wegovy (semaglutide) and Eli Lilly's Trulicity (dulaglutide) and Mounjaro (tirzepatide) and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim's Jardiance (Empagliflozin).
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
they always tease you with some good news but it is always followed up with an offering or a reverse split. Its honestly simply a pump and dump stock and if I had not already had a position that is how I would trade it. But it around .30 and wait for the pump. Its really sad what has happened to this company but its just all smoke and mirrors it seems.
Poor rdhl I’ve always believed in you and you’ve always broken my lil heart WHY!!!!
You had so much potential.
the worst possible thing they could do at this point is another reverse split and that is what they are doing. I am selling out this stock was such a waste of time and money
another dreaded reverse split. Shorts will cut the price in half within weeks after the split. I will likely unload half my position today as there is just no future here.
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
https://finance.yahoo.com/news/redhill-biopharma-announces-plan-implement-110000303.html
TEL AVIV, Israel and RALEIGH, N.C., Aug. 16, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to implement a ratio change of the Company's American Depositary Shares (ADSs) to its non-traded ordinary shares from the current ratio of one (1) ADS representing four hundred (400) ordinary shares to a new ratio of one (1) ADS representing ten thousand (10,000) ordinary shares. The anticipated first date of the ratio change is on or about August 20, 2024, and the Company's ADSs will continue to be traded on the Nasdaq Capital Market ("Nasdaq") under the symbol "RDHL" with a new CUSIP Number 757468301.
For ADS holders, the ratio change will have the same effect as a one-for-25 reverse ADS split. No new ADSs will be issued in connection with the change in the ADS ratio. ADS holders will not be required to take any action and, on the effective date, the Bank of New York Mellon, the depositary bank for RedHill's ADS program, will arrange for the exchange of every twenty-five (25) existing ADSs held for one (1) new ADS.
No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated, and the depositary bank will attempt to sell them with the net cash proceeds from the sale of the fractional ADS entitlements to be distributed to the applicable ADS holders by the depositary bank.
On March 14, 2024, the Company reported that it had received notification from the Nasdaq Capital Market, LLC that it did not comply with the minimum bid price requirements set forth in Nasdaq Listing Rule 5450(a)(2) for continued listing on Nasdaq. The Company anticipates that after the ratio change, the price of its ADSs will increase proportionally and meet the Nasdaq minimum bid price requirement, however there can be no assurance that such an increase will occur.
Nothing but a pump and dump stock period. Until they get parntner nothing will ever change.
typical pump and dump which we always see so easy for day traders and shorts to control this stock its not even funny. If i was no so far underwater I would probably day trade it as well. They have no deal or partners so until that happens it the same old pump and dump.
0.5418 +0.0685 (+14.4729%)
As of 11:02 AM EDT. Market Open.
Negotiations underway?
The gain was indeed short lived.
They need somthing already lost most of the gains as usualy.
You didn't buy RDHL, yet you spam others to buy your scam software subscription.
Fact.
#1 ?
Based on nothing but what yiu've claimed as your subscribers saying so. Laughable rating. Plus, no quotes saying so.
A partner and/or a stockpiling contract by Barda
might just do it.
Well the same old same old is going to play out. Run up on some good news but then shorts run her right back down within a week. Untilt the company gets some partners of signs some deals it will just be rinse and repeat over and over.
$RDHL +98%+ #DDAmanda Video Analysis - #1 Stock Scanner/Screener
Good call!! Tagged .81 perfectly
Methinks that 4 companies are checking RDHL's data:
Abbvie, Janssen, BMS and PFE.
Hope some sort of coop is to materialize soon by any one of them.
good news but now what? They need a partner on this.
you posted this same nonsense on three different boards shortly. Who is paying you?
RDHL....................https://stockcharts.com/h-sc/ui?s=RDHL&p=W&b=5&g=0&id=p86431144783
If it breaks .60 it will fill the gap at .81
lol 41% up that don’t look like dropping like a rock lmfo
DROPPING LIKE A ROCK...RS IS NEXT
Followers
|
94
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3954
|
Created
|
02/25/13
|
Type
|
Free
|
Moderators midastouch017 |
NCI
BARDA
U.S. Department of Defense
FDA Office of Orphan Products Development
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021
Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib
(Posted 12/22/2020)
21 Ha'arba'a Street
Tel Aviv 6473921
Israel
972 3 541 3131
http://www.redhillbio.com
[1] https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1358&PID=0&IID=1899
[2] https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=17299
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |